Jun 19, 2013
Myriad Supreme Court Case Has Promising Outcome for Immunomic Therapeutics
In a case involving leading molecular diagnostic company Myriad Genetics, the Supreme Court ruled unanimously last Thursday that human genes cannot be patented.
Immunomic Therapeutics Announces Interim Data Analysis of Phase I...
The Company is pleased to report that the immunotherapeutic vaccine, JRC-LAMP-vaxa , appears to have met all of its primary safety end points.
Immunomic Therapeutics, Inc., Announces Bernard C. Rudnick's Nomination to the Board of Directors
The nomination of Mr. Rudnick to the Board occurs at a pivotal time for ITI, having recently completed its first-in-man Phase I clinical study for JRC-LAMP-vax. "Bernard C. Rudnick has extensive experience in start-ups, a long track record and success in biotech ventures.